Amgen Inc. (FRA:AMG)

Market Cap	171.47B +8.0%
Revenue (ttm)	31.30B +10.0%
Net Income	6.57B +88.5%
EPS	12.12 +88.2%
Shares Out	n/a
PE Ratio	26.11
Forward PE	16.72
Dividend	8.36 (2.64%)
Ex-Dividend Date	Feb 13, 2026

Volume	448
Average Volume	203
Open	319.35
Previous Close	319.40
Day's Range	316.00 - 322.00
52-Week Range	230.00 - 327.70
Beta	n/a
RSI	65.76
Earnings Date	Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 31,500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: AMG

Financial Performance

In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.

Financial numbers in USD